<code id='447858E5AE'></code><style id='447858E5AE'></style>
    • <acronym id='447858E5AE'></acronym>
      <center id='447858E5AE'><center id='447858E5AE'><tfoot id='447858E5AE'></tfoot></center><abbr id='447858E5AE'><dir id='447858E5AE'><tfoot id='447858E5AE'></tfoot><noframes id='447858E5AE'>

    • <optgroup id='447858E5AE'><strike id='447858E5AE'><sup id='447858E5AE'></sup></strike><code id='447858E5AE'></code></optgroup>
        1. <b id='447858E5AE'><label id='447858E5AE'><select id='447858E5AE'><dt id='447858E5AE'><span id='447858E5AE'></span></dt></select></label></b><u id='447858E5AE'></u>
          <i id='447858E5AE'><strike id='447858E5AE'><tt id='447858E5AE'><pre id='447858E5AE'></pre></tt></strike></i>

          hotspot

          hotspot

          author:explore    Page View:56886
          Surgeons look over an x-ray monitor showing an implanted pacemaker — coverage from STAT
          Adobe

          In her final presentation for health policy class at the University of Chicago, first-year medical student Robin Ji informed her classmates that the Food and Drug Administration does not require randomized controlled trials of most medical devices. Her peers’ immediate reaction was disbelief.

          “One classmate kept asking me, are you sure?” Ji said. “I think he asked me twice. Then he went on his phone to check to see if it was actually true.”

          advertisement

          Ji was sure. She had spent two years before going to medical school working as a policy analyst for Rita Redberg and Sanket Dhruva, medical safety experts at the University of California, San Francisco. In a recent national survey published by the UCSF team in Health Affairs, Ji learned that it’s not just her classmates who may have misconceptions about the FDA — only 17% of physicians surveyed felt they understood the FDA’s device approval process. Around 41% felt they understood the drug side.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more
          Custom gene therapy hints at new path for rare disease treatments
          Custom gene therapy hints at new path for rare disease treatments

          AdobeWhenTimothyYudevelopedmilasen,acustomdrugforayounggirlnamedMilawithBattendisease,heignitedaspar

          read more
          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more

          Cosmetics set for new safety regulation. Why the industry is on board

          AlbertoPellaschiar/APWASHINGTON—ForthosealreadyfelledbyfumesfromtheBrazilianBlowout,itmightbesmallco